ClinicalTrials.gg
CompletedNCT03058289IT-01Updated Feb 27, 2025Results posted

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

A Phase 1/2 interventional study of INT230-6 and anti-PD-1 antibody in Breast Cancer, Head and Neck Cancer and Squamous Cell Carcinoma, sponsored by Intensity Therapeutics, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Intensity Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 21 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
111
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.

Read the detailed description

INT230-6 is comprised of 3 agents in a fixed ratio - a cell permeation enhancer and two, potent anti-cancer payloads (cisplatin and vinblastine sulfate). The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Nonclinical safety studies showed no findings following drug injection into healthy tissues.

Historically physicians administer the two active drugs comprising INT230-6 by intravenous (IV) infusion to achieve a systemic blood level at the limit of tolerability. The objective is destroy both visible tumors and unseen circulating cancer cells (micro-metastases). Unfortunately, dosing drugs IV delivers only a small amount with a low concentration at the tumor site. This approach especially for late stage cancers is not highly effective and often quite toxic to the patient.

Attempts at direct intratumoral injection with chemotherapeutic agents have not shown the ability to treat the injected tumor, non-injected tumors or micro-metastases. This lack of efficacy for local administration is due possibly to poor dispersion and a lack of cell uptake of the agents.

Due to the use of the novel cell penetration enhancing agent INT230-6 treatment demonstrated strong efficacy in animals having large tumors. The Sponsor's in vivo, non-clinical data shows that INT230-6 thoroughly saturates and kills injected tumors. In addition, the drug induces an adaptive (T-cell mediated) immune response that attacks not only the injected tumor, but non-injected tumors and unseen micro-metastases. Cured animals become permanently immunized against the type of cancer that INT230-6 eliminates.

Clinical trial IT-01 sought to determine the safety and potential efficacy of dosing INT230-6 directly into several different types of cancers. In addition, animal studies showed a strong synergy of INT230-6 with immune modulation agents. Thus, as part of study IT-01 the Sponsor seeks to understand the safety and efficacy of INT230-6 when administered in combination with immuno-therapeutic agents such as antibodies that target Programmed Cell Death (PD-1 or anti-PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4 or anti-CTLA-4) receptors.

This study sought to understand whether tumor regression can be achieved, and patient outcomes improved.

02

Conditions studied

  • Breast Cancer
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Lymphoma
  • Pancreatic Cancer
  • Liver Cancer
  • Colon Cancer
  • Lung Cancer
  • Bile Duct Cancer
  • Chordoma of Sacrum
  • Sarcoma

Keywords

  • Neoplasm
  • Malignancy
  • Intratumoral
  • Intralesional
  • anti-PD-1 antibodies
  • Immuno therapy
  • Dose escalation
  • Platinum
  • Intensity Therapeutics
  • INT230-6
  • Cisplatin
  • Vinblastine
  • PD-1
  • Vinca
  • KEYTRUDA®
  • Pembrolizumab
  • CTLA-4
  • Carcinoma
  • Yervoy
  • Ipilimumab
  • Keynote A10
  • CA184-592
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 111 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Intensity Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

INT230-6 monotherapy Cohorts EC2 and EC3, combination with KEYTRUDA® cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria will be noted.

  1. The participant (or legally acceptable representative if applicable) provides written for the trial.
  2. Men and Women > 18 years of age on the day of signing consent.
  3. Have an (ECOG) performance status \< 2; (for pembrolizumab and ipilimumab combinations please see supplements DEC/DEC2 and FEC for ECOG criteria).
  4. Populations: INT230-6 will be injected into deep or superficial tumors for subjects with or cytologically confirmed advanced or cancers; (for pembrolizumab and ipilimumab combinations please see supplements DEC/DEC2 and FEC for Populations).
  5. Includes subjects with loco-regional disease that have /recurred within 6 months of chemo-radiation and who have no standard of care.
  6. Subjects with metastatic disease who have failed one or more approved standard therapies, or have no alternate approved therapy available. Failure of all approved therapies that have a modest or marginal impact on survival is not required as long as the treating physician believes that treatment on study is appropriate for the subject and documents that the subject elects to defer the approved therapies.

    Note: There is no limit on the number of prior therapies that a patient (subject) may have received prior to enrollment in any cohort.

  7. Subjects must have by 1.1 criteria including one target tumor for injection by the local site investigator/radiology. Superficial tumors must have one tumor greater than or equal to 1.0 cm, deep tumors greater than or equal to 1.0 cm (as measured by caliper (for non-injected tumors only) or image guidance). Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  8. Subjects must have a minimum of one injectable lesion as determined by the investigator (for superficial tumors) or radiologist (deep tumors).
  9. Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to dosing (with the exception of kinase inhibitors or other short half-life drugs, a 2 week washout is acceptable prior to treatment) and all adverse events have either returned to baseline or stabilized.

    Note: Subjects who have received prior platinum therapy are eligible irrespective of their response.

  10. Prior systemic radiation therapy (either IV, intrahepatic or oral) completed at least 4 weeks prior to study drug administration; (for ipilimumab combination please see supplement FEC exclusion criteria).
  11. Prior focal radiotherapy completed at least 2 weeks prior to study drug administration.
  12. Prior major treatment-related surgery completed at least 4 weeks prior to study drug administration.
  13. No prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable as well as off therapy for at least 2 months.
  14. ≥8 weeks; (for ipilimumab combination please see supplement FEC inclusion criteria).
  15. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP)
    2. A WOCBP subject who may become pregnant or who are sexually active with a partner and who could become pregnant agrees to use an effective form of barrier during the study and for at least 180 days in monotherapy; (for pembrolizumab and ipilimumab combinations please see supplements DEC/DEC2 and FEC for pregnancy criteria). (Male subjects must agree to use contraception and refrain from sperm donation during the study for 180 days after administration of study drug.)
  16. Have adequate organ function as defined by the below screening laboratory values that must meet the following criteria:

    1. WBC ≥2000/μL (≥2 x 109/L).
    2. Neutrophils ≥1000/μL (≥1 x 109/L); (for pembrolizumab and ipilimumab combinations please see supplements DEC/DEC2 and FEC for neutrophil criteria).
    3. For subjects with planned superficial only injections: PT, /aPTT, and INR ≤1.5 × , ≥70x103/μL (≥ 70 x 109/L), ≥8 g/dL
    4. Creatinine within the institution's laboratory upper limit of normal or calculated >50 ml/min; (for pembrolizumab combination please see supplements DEC/DEC2 for creatine criteria).
    5. (SGOT)/AST (SGPT) ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases.
    6. ≤2 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin \<3.0 mg/dL (\<52 µmol/L); (for pembrolizumab and ipilimumab combinations please see supplements DEC/DEC2 and FEC for bilirubin criteria).
    7. For subjects with planned deep tumor injections: PT, PTT/aPPT, and INR within normal limits; Platelet count ≥100,000/μL; hemoglobin ≥ 9 g/dL.

      Note: ALT (SGPT) =alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT) =aspartate aminotransferase (serum glutamic oxaloacetic transaminase); ULN=upper limit of normal.

      1 Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.

  17. Additional criteria for combination arms can be found in the appropriate combination protocol supplements. Refer to the Investigative site for details.

    Additional Inclusion Criteria for DEC2 cohort (anti-PD1 combination, KEYTRUDA® (pembrolizumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Pancreatic, Cholangiocarcinoma, non-MSI-H and/or MMR proficient colorectal cancer, and Squamous Cell Carcinoma tumors.

    Additional Inclusion Criteria for FEC cohort ( combination, Yervoy (ipilimumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Hepatocellular carcinoma (HCC), breast cancer regardless of histology (BC) or soft tissue sarcoma

    NOTE: DEC and FEC combination cohorts have additional Inclusion Criteria - refer to the Investigative site for details.

Exclusion criteria

Exclusion Criteria:

For INT230-6 Monotherapy cohort EC3, cohort DEC2-KEYTRUDA® combination and cohort FEC-Yervoy combination

Subjects who exhibit any of the following conditions at screening will not be eligible for admission into the study:

  1. History of severe reactions to cisplatin or vinblastine or other products of the same class.
  2. Other prior , except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the subject has been disease-free for at least 2 years.
  3. Subjects with tumors >15 cm (in longest diameter). Treatment plan for subjects with tumors that are 9 to15 cm must be discussed with and approved by the medical monitor.
  4. Underlying medical condition that, in the Principal Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  5. Concurrent medical condition requiring the use of medications, or systemic (topical steroids are permitted); systemic corticosteroids must be discontinued at least 4 weeks prior to dosing. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if the subject is on a stable dose. Non-absorbed intra-articular steroid injections will be permitted; or use of other drugs (drugs not marketed for any indication) within 30 days prior to study drug administration. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.
  6. For deep tumor cohorts, subjects who require uninterrupted anticoagulants of any type, on daily aspirin therapy or NSAIAs.
  7. Use of other investigational drugs (drugs not marketed for any indication) within 28 days prior to study drug administration.

Pregnancy Exclusion:

A who has a positive urine pregnancy test (e.g., within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

NOTE: DEC or FEC combination cohorts have additional Exclusion criteria. Refer to the Investigative site for details.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Monotherapy With >=40% Total Tumor Burden Dosed (Cohorts A1/B1/EA/EC/EC2/EC3)

    Dosing: \>=40% Total Tumor Burden A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor. B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor Dosing schedule for A1 and B1 is every 28 days for 5 sessions EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC. EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years. Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions Completed Cohorts

    Drug: INT230-6

  • Experimental
    Monotherapy With <40% Total Tumor Burden Dosed (Cohorts A1/B1/EA/EC/EC2/EC3)

    Dosing: \<40% Total Tumor Burden A1:INT230-6 injections into only superficial tumors, low starting dose, low concentration per tumor. B1:INT230-6 injections into deep tumors, low starting dose, low drug concentration per tumor Dosing schedule for A1 and B1 is every 28 days for 5 sessions EA:INT230-6 injections into superficial tumors, medium starting dose, low drug concentration per tumor EC:INT230-6 injections into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor EC2:INT230-6 injections into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC. EC3:INT230-6 injections at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years. Dosing schedule for EA, EC, EC2 and EC3 is every 2 weeks for 5 sessions Completed Cohorts

    Drug: INT230-6

  • Experimental
    INT230-6 Combined With Pembrolizumab (Cohorts DEC/DEC2)

    DEC: INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody KEYTRUDA® (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types. Completed Cohort DEC2:INT230-6 per the dosing of cohort EC3 combined with KEYTRUDA® (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers. Completed Cohort

    Drug: INT230-6 · Biological: anti-PD-1 antibody

  • Experimental
    INT 230-6 Combined With Ipilimumab (Cohort FEC)

    FEC: INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types. Completed Cohort anti-CTLA-4 antibody: The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC.

    Drug: INT230-6 · Biological: anti-CTLA-4 antibody

Interventions

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)

    The primary objective is to assess the safety and tolerability of single and multiple intratumoral doses of INT230-6 in subjects with advanced or recurrent malignancies. This will be assessed by the rate of ≥ grade 3 AE's attributed to INT230-6 and not the underlying disease. NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 (least severe) to 5 (most severe)) All recorded adverse events will be listed and tabulated by system organ class, preferred term, and dose and coded according to the most current version of MedDRA. The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance. Adverse Events will be summarized for all reported data and by study period: a) up to and including 28 days post last dose of initial treatment, and b) from first dose of re-initiation of treatment, for subjects who re-initiate study therapy while in follow-up, up to 28 days post-dose of the last re-treatment dose.

    Time frame: Up to 5 years

Secondary outcomes

  1. Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria,

    Assess the preliminary efficacy of INT230-6 by measuring the disease control rate (CR+PR+SD) as assessed by iRECIST. Complete response (CR) and partial response (PR) will be defined for injected tumors followed per RECIST 1.1 utilizing target lesions. Progressive disease will be determined by clinical or radiological deterioration leading to the subject being taken off-treatment at the discretion of the investigator. Stable disease (SD) is defined as any adequate assessment not considered CR, PR, or progression.

    Time frame: Up to 5 years

  2. Determine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Components of INT230-6.

    Characterize the peak plasma profile for the three INT230-6 components after single and then multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 1 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

    Time frame: T = 1 hour after first dose

  3. Determine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of the 3 Main Components of INT230-6.

    Characterize the pharmacokinetic AUC profile of each of the three INT230-6 components for AUC after single IT tumor site injection for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

    Time frame: T= 0, 1, 3, 6, 24 Hours after dosing

  4. Key Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT230-6.

    Characterize the half life of each of the three INT230-6 components after single and multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

    Time frame: T= 0, 1, 3, 6, 24 hours

Other outcomes

  1. Exploratory: Control or Regression of Non Injected Tumors by Measurement of Length (in Centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging.

    Characterize response in non-injected lesions (up to 5) using length (cm) as the key parameter for measurement.

    Time frame: Up to 18 months

  2. Exploratory: Blood, Genetic and Tissue Biomarker Identification From Cell Flow Phenotyping, Tissue Analysis, Genetic SNP Analysis.

    Evaluate various tumor and anti-tumor immune response biomarkers from blood, tumor tissue that may correlate with tumor response. Flow and tissue panels may include Live-Dead, CD3, CD4, CD8, FoxP3, Ki-67, ICOS, DAPI, PD-1, LAG-3, TIM-3, CTLA-4 and analysis of blood serum cytokine such as Th1/Th2, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, and TNF-α.

    Time frame: Up to 2 months

  3. Exploratory: Overall Subject Outcome

    Evaluate overall response by iRECIST including survival

    Time frame: Up to 3 years

07

Results

Posted Aug 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneMonotherapy: Cohort A1Monotherapy: Cohort B1Monotherapy: Cohort EAMonotherapy: Cohort ECMonotherapy: Cohort EC-2Monotherapy: Cohort EC3INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)
Started6442120962218
Completed1119933513
Not completed533121163175
Withdrew: Radiographic deterioration031263042
Withdrew: Adverse event201310130
Withdrew: Withdrawal by subject000202041
Withdrew: Physician decision100210230
Withdrew: Clinical deterioration200211032
Withdrew: Lost to follow-up000010000
Withdrew: Refused further treatment001010000
Withdrew: Rapid progression of disease000100000

Outcome measures

PrimaryRate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)

The primary objective is to assess the safety and tolerability of single and multiple intratumoral doses of INT230-6 in subjects with advanced or recurrent malignancies. This will be assessed by the rate of ≥ grade 3 AE's attributed to INT230-6 and not the underlying disease. NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 (least severe) to 5 (most severe)) All recorded adverse events will be listed and tabulated by system organ class, preferred term, and dose and coded according to the most current version of MedDRA. The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance. Adverse Events will be summarized for all reported data and by study period: a) up to and including 28 days post last dose of initial treatment, and b) from first dose of re-initiation of treatment, for subjects who re-initiate study therapy while in follow-up, up to 28 days post-dose of the last re-treatment dose.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)
ParticipantsMonotherapy: Cohort A1Monotherapy: Cohort B1Monotherapy: Cohort EAMonotherapy: Cohort ECMonotherapy: Cohort EC-2Monotherapy: Cohort EC3INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)
Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)001240162
SecondaryPreliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria,

Assess the preliminary efficacy of INT230-6 by measuring the disease control rate (CR+PR+SD) as assessed by iRECIST. Complete response (CR) and partial response (PR) will be defined for injected tumors followed per RECIST 1.1 utilizing target lesions. Progressive disease will be determined by clinical or radiological deterioration leading to the subject being taken off-treatment at the discretion of the investigator. Stable disease (SD) is defined as any adequate assessment not considered CR, PR, or progression.

Time frame:
Up to 5 years
Reported as:
Number · percentage (DCR)
Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria,
percentage (DCR)Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed >/= 40%TTB]Monotherapy (Cohorts A1/B1/EA/EC/EC2/EC3) [Dosed <40%TTB]INT230-6 Combined With Pembrolizumab (Cohorts DEC/DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)
Preliminary Efficacy: Assess the Preliminary Efficacy of INT230-6 by Measuring the Disease Control Rate (DCR) Based on the Response Evaluation Criteria in Solid Tumors (RECIST) and Immune RECIST (iRECIST) Criteria,83.350.064.383.3
SecondaryDetermine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Components of INT230-6.

Characterize the peak plasma profile for the three INT230-6 components after single and then multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 1 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

Time frame:
T = 1 hour after first dose
Reported as:
Mean · ng/mL
Determine Pharmacokinetic Parameter Peak Plasma (Cmax in ng/mL) of Each of the 3 Main Components of INT230-6.
ng/mLPharmacokinetic (PK) Analysis Population (Component 1: Cisplatin)Pharmacokinetic Analysis Population (Component 2: SHAO)Pharmacokinetic Analysis Population (Component 3: Vinblastine)
Mean INT230-6 Dose Category: 2mL34.27 ± 25.5174.93 ± 70.81.35 ± 1.7
Mean INT230-6 Dose Category: 5mL77.81 ± 38.16113.7 ± 83.2.73 ± .77
Mean INT230-6 Dose Category: 10mL153.8 ± 65.75300.6 ± 172.6.75 ± .33
Mean INT230-6 Dose Category: 17mL245.8 ± 119.3426.8 ± 306.61.24 ± .67
Mean INT230-6 Dose Category: 30mL456.5 ± 195.0911.6 ± 790.13.16 ± 1.99
Mean INT230-6 Dose Category: 68mL952.2 ± 503.81446 ± 12455.63 ± 2.33
Mean INT230-6 Dose Category: 118mL1673 ± 12762720 ± 18489.52 ± 4.52
SecondaryDetermine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of the 3 Main Components of INT230-6.

Characterize the pharmacokinetic AUC profile of each of the three INT230-6 components for AUC after single IT tumor site injection for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

Time frame:
T= 0, 1, 3, 6, 24 Hours after dosing
Reported as:
Mean · ng/mL
Determine Key Pharmacokinetic Parameter, Area Under the Curve (AUC) (ng/mL) of Each of the 3 Main Components of INT230-6.
ng/mLPharmacokinetic (PK) Analysis Population (Component 1: Cisplatin)Pharmacokinetic Analysis Population (Component 2: SHAO)Pharmacokinetic Analysis Population (Component 3: Vinblastine)
Mean INT230-6 Dose Category: 2mL Time point: 0 Hours6.38 ± 20.180 ± 0.33 ± 1.05
Mean INT230-6 Dose Category: 2mL Time point: 1 Hour(s)33.78 ± 24.9259.94 ± 69.95.08 ± .16
Mean INT230-6 Dose Category: 2mL Timepoint: 3 Hours28.09 ± 23.163.33 ± 6.99.04 ± .12
Mean INT230-6 Dose Category: 2mL Timepoint: 6 Hours25.35 ± 20.350 ± 00 ± 0
Mean INT230-6 Dose Category: 2mL Timepoint: 24 Hours20.74 ± 17.220 ± 00 ± 0
Mean INT230-6 Dose Category: 5mL Timepoint: 0 Hours1.56 ± 4.670 ± 00 ± 0
Mean INT230-6 Dose Category: 5mL Timepoint: 1 Hour(s)77.81 ± 38.16113.74 ± 83.23.65 ± .76
Mean INT230-6 Dose Category: 5mL Timepoint: 3 Hours58.50 ± 30.5711.43 ± 15.52.16 ± .16
Mean INT230-6 Dose Category: 5mL Timepoint: 6 Hours59.04 ± 32.032.18 ± 6.150 ± 0
Mean INT230-6 Dose Category: 5mL Timepoint: 24 Hours53.87 ± 29.070 ± 00 ± 0
Mean INT230-6 Dose Category: 10mL Timepoint: 0 Hours4.95 ± 13.090 ± 00 ± 0
Mean INT230-6 Dose Category: 10mL Timepoint: 1 Hour(s)152.63 ± 67.36300.56 ± 172.62.74 ± .35
Mean INT230-6 Dose Category: 10mL Timepoint: 3 Hours114.7 ± 53.3836.68 ± 51.13.39 ± .22
Mean INT230-6 Dose Category: 10mL Timepoint: 6 Hours111.57 ± 49.376.21 ± 15.22.34 ± .1
Mean INT230-6 Dose Category: 10mL Timepoint: 24 Hours100.98 ± 52.360 ± 0.05 ± .12
Mean INT230-6 Dose Category: 17mL Timepoint: 0 Hours4.99 ± 19.500 ± 0.01 ± .06
Mean INT230-6 Dose Category: 17mL Timepoint: 1 Hours233.15 ± 125.77426.75 ± 306.591.2 ± .72
Mean INT230-6 Dose Category: 17mL Timepoint: 3 Hours187.08 ± 93.2259.76 ± 45.33.66 ± .35
Mean INT230-6 Dose Category: 17mL Timepoint: 6 Hours176.45 ± 90.2619.49 ± 19.77.51 ± .29
Mean INT230-6 Dose Category: 17mL Timepoint:24 Hours163.87 ± 90.19.5 ± 2.27.17 ± .24
Mean INT230-6 Dose Category: 30mL Timepoint: 0 Hours7.15 ± 19.240.0 ± 00 ± 0
Mean INT230-6 Dose Category: 30mL Timepoint: 1 Hours456.47 ± 195.02911.55 ± 790.143.16 ± 1.99
Mean INT230-6 Dose Category: 30mL Timepoint: 3 Hours344.82 ± 163.1295.67 ± 64.381.44 ± .77
Mean INT230-6 Dose Category: 30mL Timepoint: 6 Hours325.73 ± 152.9126.95 ± 20.341.06 ± .58
Mean INT230-6 Dose Category: 30mL Timepoint: 24 Hours295.42 ± 137.46.78 ± 3.20.47 ± .38
Mean INT230-6 Dose Category: 68mL Timepoint: 0 Hours62.93 ± 222.70289.23 ± 1042.84.44 ± 1.58
Mean INT230-6 Dose Category: 68mL Timepoint: 1 Hours832.92 ± 192.931286.00 ± 1039.435.53 ± 2.35
Mean INT230-6 Dose Category: 68mL Timepoint: 3 Hours741.92 ± 343.37240.82 ± 276.132.73 ± .72
Mean INT230-6 Dose Category: 68mL Timepoint: 6 Hours775.00 ± 581.4496.54 ± 146.881.94 ± .55
Mean INT230-6 Dose Category: 68mL Timepoint: 24 Hours610.08 ± 264.392.71 ± 6.44.94 ± .43
Mean INT230-6 Dose Category: 118mL Timepoint: 0 Hours0 ± 00 ± 0.08 ± .17
Mean INT230-6 Dose Category: 118mL Timepoint: 1 Hours1664 ± 1287.532719.75 ± 1848.179.52 ± 4.52
Mean INT230-6 Dose Category: 118mL Timepoint: 3 Hours875 ± 433.39459.67 ± 289.464.33 ± 1.46
Mean INT230-6 Dose Category: 118mL Timepoint: 6 Hours779.67 ± 360.88183.43 ± 99.643.08 ± .85
Mean INT230-6 Dose Category: 118mL Timepoint: 24 Hours945.33 ± 544.7821.93 ± 24.841.24 ± 1.19
SecondaryKey Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT230-6.

Characterize the half life of each of the three INT230-6 components after single and multiple IT tumor site injections for safety purposes. Timepoints for sample collection were T = 0, 1, 3, 6, 24 Hours after dosing. Mean dose volume categories that were used to summarize data were as follows: 2 mL (range 0 to 3.5 mL) 5 mL (range 3.6 to 6 mL) 10 mL (range \>6 to 12 mL) 17 mL (range \>12 to 24 mL) 30 mL (range \>24 mL to 44 mL) 68 mL (range \>44 to 98 mL) 118 mL (range \>98 to 175 mL)

Time frame:
T= 0, 1, 3, 6, 24 hours
Reported as:
Mean · Hours
Key Pharmacokinetic Parameters, Half Live (Hours) of Each of the 3 Main Components of INT230-6.
HoursPharmacokinetic (PK) Analysis Population (Component 1: Cisplatin)Pharmacokinetic Analysis Population (Component 2: SHAO)Pharmacokinetic Analysis Population (Component 3: Vinblastine)
Mean INT230-6 Dose Category: 2mL77.98 ± 34.92——
Mean INT230-6 Dose Category: 5mL130.4 ± 129.8——
Mean INT230-6 Dose Category: 10mL106.3 ± 53.58—18.82
Mean INT230-6 Dose Category: 17mL78.73 ± 66.367.3320.11 ± 7.45
Mean INT230-6 Dose Category: 30mL64.77 ± 15.187.4815.35 ± 4.38
Mean INT230-6 Dose Category: 68mL129.4 ± 125.53.91 ± 2.614.06 ± 3.7
Mean INT230-6 Dose Category: 118mL—6.1824.48 ± 4.76
Other pre-specifiedExploratory: Control or Regression of Non Injected Tumors by Measurement of Length (in Centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging.

Characterize response in non-injected lesions (up to 5) using length (cm) as the key parameter for measurement.

Time frame:
Up to 18 months

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Blood, Genetic and Tissue Biomarker Identification From Cell Flow Phenotyping, Tissue Analysis, Genetic SNP Analysis.

Evaluate various tumor and anti-tumor immune response biomarkers from blood, tumor tissue that may correlate with tumor response. Flow and tissue panels may include Live-Dead, CD3, CD4, CD8, FoxP3, Ki-67, ICOS, DAPI, PD-1, LAG-3, TIM-3, CTLA-4 and analysis of blood serum cytokine such as Th1/Th2, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, and TNF-α.

Time frame:
Up to 2 months

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Overall Subject Outcome

Evaluate overall response by iRECIST including survival

Time frame:
Up to 3 years

Results for this outcome have not been posted.

Adverse events

Collected over Each patient would have their Adverse Events recorded starting at the first dose until 28 days after the last dose. up to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy: (Cohort A1)0/6 (0%)0/6 (0%)4/6 (66.7%)
Monotherapy: (Cohort B1)0/4 (0%)0/4 (0%)2/4 (50%)
Monotherapy: (Cohort E-A)0/4 (0%)0/4 (0%)3/4 (75%)
Monotherapy: (Cohort E-C)0/21 (0%)1/21 (4.8%)20/21 (95.2%)
Monotherapy: (Cohort EC-2)0/20 (0%)1/20 (5%)20/20 (100%)
Monotherapy: (Cohort EC3)0/9 (0%)1/9 (11.1%)7/9 (77.8%)
INT230-6 Combined With Pembrolizumab (Cohorts DEC)0/8 (0%)2/8 (25%)7/8 (87.5%)
INT230-6 Combined With Pembrolizumab (Cohorts DEC2)0/22 (0%)2/22 (9.1%)19/22 (86.4%)
INT 230-6 Combined With Ipilimumab (Cohort FEC)0/18 (0%)1/18 (5.6%)16/18 (88.9%)
Most frequent serious events
Most frequent serious events
EventMonotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT230-6 Combined With Pembrolizumab (Cohorts DEC)INT230-6 Combined With Pembrolizumab (Cohorts DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)
VomitingGastrointestinal disorders0/60/40/40/210/200/91/80/220/18
HeadacheNervous system disorders0/60/40/40/210/200/91/80/220/18
Localized Tumor Related PainGeneral disorders0/60/40/40/211/201/90/80/220/18
ColitisGastrointestinal disorders0/60/40/40/210/200/90/80/221/18
Procedural PainInjury, poisoning and procedural complications0/60/40/41/210/200/90/80/220/18
SepsisInfections and infestations0/60/40/40/210/200/90/81/220/18
PneumothoraxRespiratory, thoracic and mediastinal disorders0/60/40/40/210/200/90/81/220/18
Most frequent other events
Showing 10 of 80
Most frequent other events
EventMonotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT230-6 Combined With Pembrolizumab (Cohorts DEC)INT230-6 Combined With Pembrolizumab (Cohorts DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)
Localized Tumor-Related PainGeneral disorders2/62/43/413/2114/206/95/810/229/18
NauseaGastrointestinal disorders0/60/40/411/2110/205/92/82/224/18
FatigueGeneral disorders1/60/40/411/218/200/90/86/226/18
VomitingGastrointestinal disorders0/60/40/410/216/201/93/83/223/18
Decreased AppetiteMetabolism and nutrition disorders0/60/40/47/217/201/91/83/222/18
AnaemiaBlood and lymphatic system disorders0/60/40/42/216/200/90/82/222/18
Injection Site ErythemaGeneral disorders0/61/40/41/210/200/90/80/220/18
PyrexiaGeneral disorders0/60/41/40/211/201/90/80/222/18
HeadacheNervous system disorders0/60/41/41/210/200/91/80/222/18
UrticariaSkin and subcutaneous tissue disorders0/60/41/41/210/200/90/80/220/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
<=18 years0000000000
Between 18 and 65 years5241495481263
>=65 years1207114214647
Age, Continuous
Age, Continuous(years)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
Mean54.5 ± 7.161.5 ± 7.957.6 ± 4.159.0 ± 9.964.6 ± 9.461.5 ± 11.364.2 ± 1668.4 ± 7.364.2 ± 11.162.9 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
Female4321176381054
Male21210133314856
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
Hispanic or Latino00122203313
Not Hispanic or Latino643191876191597
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
American Indian or Alaska Native0000000000
Asian01032215115
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1002000227
White534161855131382
More than one race0000000000
Unknown or Not Reported0000020226
Region of Enrollment
Region of Enrollment(participants)Monotherapy: (Cohort A1)Monotherapy: (Cohort B1)Monotherapy: (Cohort E-A)Monotherapy: (Cohort E-C)Monotherapy: (Cohort EC-2)Monotherapy: (Cohort EC3)INT 230-6 Combined With Pembrolizumab (Cohort DEC)INT 230-6 Combined With Pembrolizumab (Cohort DEC2)INT 230-6 Combined With Ipilimumab (Cohort FEC)Total
Canada30011041111
United States344201992211799
08

Study locations

8 sites
  • USC Norris
    Los Angeles, California 90033, United States
  • USC HOAG
    Newport Beach, California 92663, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21205, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
  • Center for Oncology and Blood Disorders
    Houston, Texas 77030, United States
  • Princess Margaret Cancer Center - University Health Network
    Toronto, Ontario M5G 1Z5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Feb 2023, 72 months.

Results were first posted in Aug 2024, 1 year 5 months after primary completion.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 72 months is above that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2017
First posted
Feb 20, 2017
StartActual
Feb 9, 2017
Primary completionActual
Feb 22, 2023
CompletionActual
Feb 22, 2023
Results first posted
Aug 13, 2024
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03058289
Lead sponsor
Intensity Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2017
Start date
Feb 9, 2017
Primary completion
Feb 22, 2023
Completion
Feb 22, 2023
Results posted
Aug 13, 2024
Last update
Feb 27, 2025

Study contacts

Brian Schwartz, M.D.
study director · Intensity Therapeutics
Lillian Siu, M.D., FRCP
study chair · Princess Margaret Hospital, Canada
Anthony El-Khoueiry, M.D.
principal investigator · USC Norris and HOAG sites
Anthony J. Olszanski, M.D., RPh
principal investigator · Fox Chase Cancer Center
Nilofer Azad, M.D.
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Giles F Whalen, M.D.
principal investigator · UMASS Memorial Medical Group
Matthew Ingham, M.D.
principal investigator · Columbia University
Luis Camacho, M.D.
principal investigator · Center for Oncology and Blood Disorders

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6

Start the discussion